BG64694B1 - Полиол - интерферон - бета конюгати - Google Patents
Полиол - интерферон - бета конюгати Download PDFInfo
- Publication number
- BG64694B1 BG64694B1 BG104871A BG10487100A BG64694B1 BG 64694 B1 BG64694 B1 BG 64694B1 BG 104871 A BG104871 A BG 104871A BG 10487100 A BG10487100 A BG 10487100A BG 64694 B1 BG64694 B1 BG 64694B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- polyol
- peg
- ifn
- interferon
- thiol
- Prior art date
Links
- 108090000467 Interferon-beta Proteins 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 42
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 230000001363 autoimmune Effects 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 208000015181 infectious disease Diseases 0.000 claims abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 106
- 239000002202 Polyethylene glycol Substances 0.000 claims description 96
- 150000003077 polyols Chemical group 0.000 claims description 21
- 102000003996 Interferon-beta Human genes 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 229940079322 interferon Drugs 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229920005862 polyol Polymers 0.000 claims description 12
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- -1 polyethylene Polymers 0.000 claims description 7
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 230000001588 bifunctional effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 3
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- AWAFMFHOLVZLFG-UHFFFAOYSA-N 1-iodoaziridine-2,3-dione Chemical compound IN1C(=O)C1=O AWAFMFHOLVZLFG-UHFFFAOYSA-N 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 abstract description 63
- 229920001184 polypeptide Polymers 0.000 abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 20
- 230000006320 pegylation Effects 0.000 abstract description 16
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 abstract description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract description 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- 101100498071 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-17 gene Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000000840 anti-viral effect Effects 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 238000005227 gel permeation chromatography Methods 0.000 description 8
- 238000005251 capillar electrophoresis Methods 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000012911 assay medium Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical class OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- BTBWSRPRAGXJJV-UHFFFAOYSA-N 2h-benzotriazole;carbonic acid Chemical class OC(O)=O.C1=CC=C2NN=NC2=C1 BTBWSRPRAGXJJV-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000219112 Cucumis Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101000654530 Tupaia virus (isolate Tupaia/Thailand/-/1986) Small hydrophobic protein Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000008431 aliphatic amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 102000051179 human NCKIPSD Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8333998P | 1998-04-28 | 1998-04-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG104871A BG104871A (en) | 2001-07-31 |
| BG64694B1 true BG64694B1 (bg) | 2005-12-30 |
Family
ID=22177687
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104871A BG64694B1 (bg) | 1998-04-28 | 2000-10-17 | Полиол - интерферон - бета конюгати |
| BG109291A BG65046B1 (bg) | 1998-04-28 | 2000-10-17 | Метод за степенно прикрепване на полиетиленгликолкъм полипептид |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG109291A BG65046B1 (bg) | 1998-04-28 | 2000-10-17 | Метод за степенно прикрепване на полиетиленгликолкъм полипептид |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US6638500B1 (cs) |
| EP (2) | EP1421956B1 (cs) |
| JP (2) | JP4574007B2 (cs) |
| KR (1) | KR100622796B1 (cs) |
| CN (2) | CN100335503C (cs) |
| AR (1) | AR020070A1 (cs) |
| AT (2) | ATE275422T1 (cs) |
| AU (1) | AU762621B2 (cs) |
| BG (2) | BG64694B1 (cs) |
| BR (1) | BR9910023A (cs) |
| CA (2) | CA2330451A1 (cs) |
| CY (1) | CY1108022T1 (cs) |
| CZ (2) | CZ298597B6 (cs) |
| DE (2) | DE69936409T2 (cs) |
| DK (2) | DK1075281T3 (cs) |
| EA (2) | EA005495B1 (cs) |
| EE (1) | EE05214B1 (cs) |
| ES (2) | ES2285286T3 (cs) |
| HU (1) | HUP0300548A3 (cs) |
| IL (1) | IL139286A (cs) |
| NO (2) | NO329749B1 (cs) |
| NZ (1) | NZ507456A (cs) |
| PL (2) | PL196533B1 (cs) |
| PT (2) | PT1075281E (cs) |
| SI (2) | SI1075281T1 (cs) |
| SK (2) | SK286217B6 (cs) |
| TR (2) | TR200003161T2 (cs) |
| TW (2) | TWI232882B (cs) |
| UA (2) | UA66857C2 (cs) |
| WO (1) | WO1999055377A2 (cs) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
| US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
| LT2599503T (lt) | 1998-10-16 | 2017-06-26 | Biogen Ma Inc. | Interferono beta-1a polimero konjugatai ir jų panaudojimas |
| WO2000023472A2 (en) | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
| CN1244376C (zh) * | 1999-04-23 | 2006-03-08 | 阿尔萨公司 | 可释放的键和含有该键的组合物 |
| US7303760B2 (en) * | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
| US7238368B2 (en) * | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
| US7431921B2 (en) | 1999-08-27 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
| US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
| US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| TR200101086A3 (cs) * | 1999-10-15 | 2001-08-21 | ||
| JP4593048B2 (ja) | 1999-12-24 | 2010-12-08 | 協和発酵キリン株式会社 | 分岐型ポリアルキレングリコール類 |
| ES2327606T3 (es) | 2000-01-10 | 2009-11-02 | Maxygen Holdings Ltd | Conjugados de g-csf. |
| WO2001058935A2 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| CA2436623C (en) | 2001-01-30 | 2011-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Branched polyalkylene glycols |
| EP1234583A1 (en) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| YU48703A (sh) | 2001-02-27 | 2006-05-25 | Maxygen Aps | Novi interferonu beta-slični molekuli |
| HUP0400466A3 (en) | 2001-07-11 | 2006-01-30 | Maxygen Holdings Ltd Georgetow | G-csf conjugates |
| GEP20074024B (en) | 2002-01-18 | 2007-01-10 | Biogen Idec Inc | Polyalkylene glycol comprising a radical for conjugation of biologically active compound |
| TWI334785B (en) | 2002-06-03 | 2010-12-21 | Serono Lab | Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race |
| AU2003254641A1 (en) * | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| EP1628618A4 (en) * | 2002-12-26 | 2009-09-09 | Mountain View Pharmaceuticals | POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY |
| WO2004060299A2 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
| DK1608745T3 (da) | 2003-03-20 | 2009-06-15 | Bayer Healthcare Llc | FVII eller FVIIa-Varianter |
| TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| EP2633866A3 (en) | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
| AU2005211385B2 (en) | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| AU2008201682B2 (en) * | 2004-02-02 | 2011-02-24 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
| EP1586334A1 (en) * | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugates with peg |
| JP2007538048A (ja) | 2004-05-17 | 2007-12-27 | アレス トレーディング ソシエテ アノニム | ヒドロゲル・インターフェロン製剤 |
| EA010979B1 (ru) | 2004-06-01 | 2008-12-30 | Арес Трейдинг С.А. | Стабилизированные жидкие препаративные формы интерферона |
| BRPI0510527A (pt) | 2004-06-01 | 2007-10-30 | Ares Trading Sa | método de estabilização de proteìnas |
| TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
| CN101111267B (zh) † | 2004-12-21 | 2012-12-05 | 尼克塔治疗公司 | 稳定的聚合物巯基试剂 |
| MX2007007591A (es) | 2004-12-22 | 2007-07-25 | Ambrx Inc | Metodos para expresion y purificacion de hormona de crecimiento humano recombinante. |
| KR20070090023A (ko) | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | 변형 인간 성장 호르몬 |
| SG161209A1 (en) * | 2004-12-22 | 2010-05-27 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| JP2009503111A (ja) * | 2005-08-04 | 2009-01-29 | ネクター セラピューティックス エイエル，コーポレイション | Ｇ−ｃｓｆ部分および重合体の複合体 |
| SI1917276T1 (en) | 2005-08-26 | 2018-05-31 | Ares Trading S.A. | PROCEDURE FOR PREPARATION OF GLYCOSYLATED INTERFERONE BETA |
| ZA200801923B (en) | 2005-09-01 | 2009-09-30 | Ares Trading Sa | Treatment of optic neuritis |
| US20070238656A1 (en) * | 2006-04-10 | 2007-10-11 | Eastman Kodak Company | Functionalized poly(ethylene glycol) |
| US7632492B2 (en) * | 2006-05-02 | 2009-12-15 | Allozyne, Inc. | Modified human interferon-β polypeptides |
| US20080096819A1 (en) * | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
| MX2008014971A (es) | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
| MX2008014685A (es) | 2006-05-24 | 2008-11-27 | Novo Nordisk Healthcare Ag | Analogos de factor ix con semivida prolongada in vivo. |
| CA2685596A1 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| CA2707840A1 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| AU2008340058A1 (en) * | 2007-12-20 | 2009-07-02 | Merck Serono S.A. | PEG-interferon-beta formulations |
| US9938333B2 (en) | 2008-02-08 | 2018-04-10 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| CN101525381B (zh) * | 2008-03-04 | 2012-04-18 | 北京百川飞虹生物科技有限公司 | 一种重组复合干扰素及其表达载体的构建和表达 |
| WO2009155102A2 (en) * | 2008-05-30 | 2009-12-23 | Barofold, Inc. | Method for derivatization of proteins using hydrostatic pressure |
| US20110124614A1 (en) * | 2008-10-25 | 2011-05-26 | Halina Offner | Methods And Compositions For The Treatment of Autoimmune Disorders |
| DE102009032179A1 (de) * | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
| ES2365343B1 (es) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de cd98 como marcador de receptividad endometrial. |
| JP5914363B2 (ja) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー／エス | 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子 |
| AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
| EP3372617B1 (en) | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| EP2569331A1 (en) | 2010-05-10 | 2013-03-20 | Perseid Therapeutics LLC | Polypeptide inhibitors of vla4 |
| CN102971006A (zh) | 2010-07-15 | 2013-03-13 | 诺沃—诺迪斯克有限公司 | 稳定的因子viii变体 |
| CN103209992A (zh) | 2010-09-15 | 2013-07-17 | 诺沃—诺迪斯克有限公司 | 具有减少的细胞摄取的因子viii变体 |
| JP2014506889A (ja) * | 2011-02-18 | 2014-03-20 | ステムディーアール インク． | Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物 |
| KR20140054009A (ko) | 2011-07-01 | 2014-05-08 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 릴랙신 융합 폴리펩타이드 및 그의 용도 |
| CN109134642A (zh) * | 2011-10-01 | 2019-01-04 | 株式会社糖锁工学研究所 | 加成糖链的多肽及含有该多肽的医药组合物 |
| US10172953B2 (en) | 2012-02-27 | 2019-01-08 | Amunix Operating Inc. | XTEN conjugate compositions and methods of making same |
| US20150030564A1 (en) | 2012-02-29 | 2015-01-29 | Toray Industries, Inc. | Inhibitory agent for body cavity fluid accumulation |
| WO2014157107A1 (ja) | 2013-03-29 | 2014-10-02 | 株式会社糖鎖工学研究所 | シアリル化糖鎖が付加されたポリペプチド |
| US11759500B2 (en) | 2014-07-24 | 2023-09-19 | Abion Inc. | PEGylated interferon-beta variant |
| WO2016013697A1 (ko) * | 2014-07-24 | 2016-01-28 | 에이비온 주식회사 | 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체 |
| HRP20201725T1 (hr) | 2014-08-19 | 2021-03-05 | Biogen Ma Inc. | Postupak pegilacije |
| CA2981822C (en) | 2015-05-01 | 2023-04-11 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics for treating ocular disorders |
| RU2756101C2 (ru) * | 2015-06-19 | 2021-09-28 | ЭЙСАЙ АрЭНДДи МЕНЕДЖМЕНТ КО., ЛТД. | Конъюгированные через cys80 иммуноглобулины |
| HRP20220407T1 (hr) | 2015-11-09 | 2022-05-27 | The Regents Of The University Of Colorado, A Body Corporate | Pripravci i postupci za uporabu u liječenju homocistinurije |
| US11324811B2 (en) * | 2017-04-17 | 2022-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Optimization of enzyme replacement therapy for treatment of homocystinuria |
| TWI869330B (zh) | 2017-11-24 | 2025-01-11 | 德商馬克專利公司 | 用於治療進展型多發性硬化症之克拉屈濱(cladribine)療程 |
| US20220220176A1 (en) | 2019-01-28 | 2022-07-14 | Toray Industries, Inc. | Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof |
| WO2020158690A1 (ja) | 2019-01-28 | 2020-08-06 | 東レ株式会社 | 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| WO1987000056A1 (en) * | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5208344A (en) * | 1987-07-31 | 1993-05-04 | American Home Products Corporation | Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US6231851B1 (en) * | 1994-05-18 | 2001-05-15 | Inhale Therapeutic Systems | Methods and compositions for the dry powder formulation of interferons |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| WO1995013090A1 (en) | 1993-11-10 | 1995-05-18 | Enzon, Inc. | Improved interferon polymer conjugates |
| TW565568B (en) | 1994-03-31 | 2003-12-11 | Amgen Inc | Compositions and methods for stimulating megakaryocyte growth and differentiation |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| KR0176625B1 (ko) | 1996-11-05 | 1999-04-01 | 삼성전자주식회사 | 적외선 물체검출장치 |
| DE69800640T2 (de) * | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| WO1999003887A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
-
1999
- 1999-04-28 SI SI9930662T patent/SI1075281T1/xx unknown
- 1999-04-28 DE DE69936409T patent/DE69936409T2/de not_active Expired - Lifetime
- 1999-04-28 SI SI9930974T patent/SI1421956T1/sl unknown
- 1999-04-28 KR KR1020007011587A patent/KR100622796B1/ko not_active Expired - Fee Related
- 1999-04-28 EP EP04003053A patent/EP1421956B1/en not_active Expired - Lifetime
- 1999-04-28 AT AT99920094T patent/ATE275422T1/de active
- 1999-04-28 WO PCT/US1999/009161 patent/WO1999055377A2/en active IP Right Grant
- 1999-04-28 EP EP99920094A patent/EP1075281B1/en not_active Expired - Lifetime
- 1999-04-28 CZ CZ20050048A patent/CZ298597B6/cs not_active IP Right Cessation
- 1999-04-28 DK DK99920094T patent/DK1075281T3/da active
- 1999-04-28 EA EA200300382A patent/EA005495B1/ru not_active IP Right Cessation
- 1999-04-28 DE DE69920002T patent/DE69920002T2/de not_active Expired - Lifetime
- 1999-04-28 CA CA002330451A patent/CA2330451A1/en not_active Abandoned
- 1999-04-28 HU HU0300548A patent/HUP0300548A3/hu unknown
- 1999-04-28 JP JP2000545574A patent/JP4574007B2/ja not_active Expired - Lifetime
- 1999-04-28 PL PL378728A patent/PL196533B1/pl not_active IP Right Cessation
- 1999-04-28 IL IL13928699A patent/IL139286A/xx not_active IP Right Cessation
- 1999-04-28 SK SK1622-2000A patent/SK286217B6/sk not_active IP Right Cessation
- 1999-04-28 UA UA2000116719A patent/UA66857C2/uk unknown
- 1999-04-28 NZ NZ507456A patent/NZ507456A/en not_active IP Right Cessation
- 1999-04-28 CZ CZ20003995A patent/CZ298579B6/cs not_active IP Right Cessation
- 1999-04-28 PT PT99920094T patent/PT1075281E/pt unknown
- 1999-04-28 PL PL344490A patent/PL193352B1/pl not_active IP Right Cessation
- 1999-04-28 SK SK66-2007A patent/SK286654B6/sk not_active IP Right Cessation
- 1999-04-28 AT AT04003053T patent/ATE365563T1/de active
- 1999-04-28 PT PT04003053T patent/PT1421956E/pt unknown
- 1999-04-28 CN CNB2004100898478A patent/CN100335503C/zh not_active Expired - Fee Related
- 1999-04-28 ES ES04003053T patent/ES2285286T3/es not_active Expired - Lifetime
- 1999-04-28 ES ES99920094T patent/ES2224649T3/es not_active Expired - Lifetime
- 1999-04-28 DK DK04003053T patent/DK1421956T3/da active
- 1999-04-28 EE EEP200000614A patent/EE05214B1/xx not_active IP Right Cessation
- 1999-04-28 TR TR2000/03161T patent/TR200003161T2/xx unknown
- 1999-04-28 CA CA002565375A patent/CA2565375A1/en not_active Abandoned
- 1999-04-28 UA UA20031212655A patent/UA79430C2/uk unknown
- 1999-04-28 TR TR2001/01751T patent/TR200101751T2/xx unknown
- 1999-04-28 EA EA200001111A patent/EA003789B1/ru not_active IP Right Cessation
- 1999-04-28 AU AU37674/99A patent/AU762621B2/en not_active Ceased
- 1999-04-28 CN CNB998054968A patent/CN1187094C/zh not_active Expired - Fee Related
- 1999-04-28 BR BR9910023-1A patent/BR9910023A/pt active Search and Examination
- 1999-04-29 AR ARP990101987A patent/AR020070A1/es active IP Right Grant
- 1999-07-26 TW TW088112596A patent/TWI232882B/zh active
- 1999-07-26 TW TW093123043A patent/TWI266800B/zh active
-
2000
- 2000-10-17 BG BG104871A patent/BG64694B1/bg unknown
- 2000-10-17 BG BG109291A patent/BG65046B1/bg unknown
- 2000-10-23 NO NO20005337A patent/NO329749B1/no not_active IP Right Cessation
- 2000-10-30 US US09/698,133 patent/US6638500B1/en not_active Expired - Lifetime
-
2003
- 2003-08-28 US US10/649,609 patent/US7357925B2/en not_active Expired - Fee Related
-
2007
- 2007-02-13 US US11/674,476 patent/US7700314B2/en not_active Expired - Fee Related
- 2007-07-19 CY CY20071100966T patent/CY1108022T1/el unknown
-
2010
- 2010-03-09 NO NO20100324A patent/NO332224B1/no not_active IP Right Cessation
- 2010-04-26 JP JP2010100840A patent/JP2010184929A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG64694B1 (bg) | Полиол - интерферон - бета конюгати | |
| MXPA00010223A (en) | Polyol-ifn-beta conjugates | |
| HK1076115B (en) | Polyol-ifn-beta conjugates | |
| HK1038194B (en) | Polyol-ifn-beta conjugates |